Micro RNA test for blood transfusion patients
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study looks at a tiny molecule called micro RNA-155 in patients who need regular blood transfusions. The goal is to see if it relates to the body making antibodies against the transfused blood, which could help improve transfusion care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must need regular blood transfusions to manage your condition.
- You must be at least 5 years old.
- You must have a history of receiving red blood cell transfusions on a regular basis.
- You cannot have autoimmune diseases, active infections, or inflammatory conditions.
- You cannot be taking immunosuppressive therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medicine called luspatercept to see if it safely helps children with beta-thalassemia need fewer blood transfusions or keep their hemoglobin levels stable. It is for children aged 6 to 17 who either get regular transfusions or have low hemoglobin and few transfusions.
This early study tests the safety and potential benefit of the LentiRed gene-based drug in people with transfusion-dependent beta-thalassemia (TDT) who are planning an autologous stem cell transplant. It may help reduce the severity of anemia, but the main goal at this stage is to check safety and side effects.
This study tests a special system (Hemanext One) that stores red blood cells with less oxygen, to see if it helps people with thalassemia who need regular transfusions. It may reduce side effects or improve how well the transfusions work.
This study tests an experimental medicine called YOLT-204 for people with beta-thalassemia who need regular blood transfusions. The goal is to see if this treatment is safe and if it might reduce the need for transfusions.
This trial is studying whether a blood test that measures small molecules called microRNAs can help doctors personalize the medicines used to prevent rejection after a heart transplant. If you qualify, you would help researchers learn how to better match immunosuppression to each patient's needs.
This trial tests whether giving you your own (autologous) gene-modified blood stem cells can improve transfusion-dependent beta-thalassemia and its safety. It may help people who do not have a fully matched donor and need an alternative approach to care.
Hear when a new Beta-Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.